Superiority of local antimoniate over systemic liposomal amphotericin B therapy in a Leishmania infantum cutaneous leishmaniasis

References

1. Blum J., Desjeux P., Schwartz E., Beck B., Hatz C. 2004; Treatment of cutaneous leishmaniasis among travellers. J Antimicrob Chemother 53:158–166 [View Article][PubMed]
   [Google Scholar]
2. Brown M., Noursadeghi M., Boyle J., Davidson R.N. 2005; Successful liposomal amphotericin B treatment of Leishmania braziliensis cutaneous leishmaniasis. Br J Dermatol 153:203–205 [View Article][PubMed]
   [Google Scholar]
3. Buffet P.A., Rosenthal É., Gangneux J.-P., Lightburne E., Couppié P., Morizot G., Lachaud L., Marty P., Dedet J.-P., Société de Pathologie Exotique. 2011; [Therapy of leishmaniasis in France: consensus on proposed guidelines]. Presse Med 40:173–184 (in French) [View Article][PubMed]
   [Google Scholar]
4. del Rosal T., Artigao F.B., Miguel M.J.G., de Lucas R., del Castillo F. 2010; Successful treatment of childhood cutaneous leishmaniasis with liposomal amphotericin B: report of two cases. J Trop Pediatr 56:122–124 [View Article][PubMed]
   [Google Scholar]
5. Electronic Medicines Compendium 2015 AmBisome® Summary of Product Characteristics. http://www.medicines.org.uk/emc/medicine/1236
6. French National Agency for Medicines and Health Products Safety 2015 [AmBisome® Summary of Product Characteristics]. http://agence-prd.ansm.sante.fr/php/ecodex/frames.php?specid = 65964911&typedoc = R&ref = R0254455.htm (in French)
7. Goto H., Lindoso J.A.L. 2010; Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis. Expert Rev Anti Infect Ther 8:419–433 [View Article][PubMed]
   [Google Scholar]
8. Hervás J.A., Martín-Santiago A., Hervás D., Rojo E., Mena A., Rocamora V., Dueñas J. 2012; Old World Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod. Pediatr Infect Dis J 31:97–100 [View Article][PubMed]
   [Google Scholar]
9. Lachaud L., Dedet J.P., Marty P., Faraut F., Buffet P., Gangneux J.P., Ravel C., Bastien P., Working Group for the Notification of Human Leishmanioses in France. 2013; Surveillance of leishmaniases in France, 1999 to 2012. Euro Surveill 18:20534[PubMed]
   [Google Scholar]
10. Maia C., Nunes M., Marques M., Henriques S., Rolão N., Campino L. 2013; In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp Parasitol 135:36–41 [View Article][PubMed]
    [Google Scholar]
11. Mary C., Faraut F., Lascombe L., Dumon H. 2004; Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity. J Clin Microbiol 42:5249–5255 [View Article][PubMed]
    [Google Scholar]
12. Paradisi A., Capizzi R., Zampetti A., Proietti I., De Simone C., Feliciani C., Amerio P.L. 2005; Atypical multifocal cutaneous leishmaniasis in an immunocompetent patient treated by liposomal amphotericin B. J Infect 51:e261–e264 [View Article][PubMed]
    [Google Scholar]
13. Rapp C., Imbert P., Darie H., Simon F., Gros P., Debord T., Roué R. 2003; [Liposomal amphotericin B treatment of cutaneous leishmaniasis contracted in Djibouti and resistant to meglumine antimoniate]. Bull Soc Pathol Exot 96:209–211 (in French)
    [Google Scholar]
14. Rongioletti F., Cannata G.E., Parodi A. 2009; Leishmaniasis due to L. infantum presenting as macrocheilitis and responding to liposomal amphotericin B. Eur J Dermatol 19:281–282[PubMed]
    [Google Scholar]
15. Sanofi-Aventis 2011 Glucantime® Summary of Product Characteristics. http://www.wipo.int/export/sites/www/research/en/data/sanofi/marketed_products/Glucantime.pdf
16. Solomon M., Pavlotsky F., Leshem E., Ephros M., Trau H., Schwartz E. 2011; Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica . J Eur Acad Dermatol Venereol 25:973–977 [View Article][PubMed]
    [Google Scholar]
17. WHO 2010Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series Geneva: World Health Organization;